TESARO Company Profile (NASDAQ:TSRO)


TESARO logoTESARO, Inc. is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform. Rolapitant is a potent and long-acting neurokinin-1 receptor antagonist for the prevention of chemotherapy induced nausea and vomiting. Niraparib is an orally active and potent poly (adenosine diphosphate (ADP)-ribose) polymerase inhibitor. It has various ongoing clinical trials evaluating niraparib for the treatment of ovarian or breast cancers. It has initiated a Phase I, dose escalation study for its first immuno-oncology antibody, TSR-042, which targets Programmed cell death protein 1. It has commenced pre-clinical research for its antibody candidate targeting Lymphocyte-activation gene-3 andTSR-033. It has commenced a Phase I clinical trial of TSR-042.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:TSRO
  • CUSIP: 88156910
  • Web: www.tesarobio.com
  • Market Cap: $6.15 billion
  • Outstanding Shares: 54,180,000
Average Prices:
  • 50 Day Moving Avg: $122.08
  • 200 Day Moving Avg: $133.77
  • 52 Week Range: $106.64 - $192.94
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -20.39
  • P/E Growth: -0.57
Sales & Book Value:
  • Annual Revenue: $41.25 million
  • Price / Sales: 149.21
  • Book Value: $7.38 per share
  • Price / Book: 15.39
  • EBITDA: ($485,860,000.00)
  • Net Margins: -1,301.19%
  • Return on Equity: -104.00%
  • Return on Assets: -71.79%
  • Debt-to-Equity Ratio: 0.34%
  • Current Ratio: 5.69%
  • Quick Ratio: 5.41%
  • Average Volume: 886,073 shs.
  • Beta: 1.59
  • Short Ratio: 7.96

Frequently Asked Questions for TESARO (NASDAQ:TSRO)

What is TESARO's stock symbol?

TESARO trades on the NASDAQ under the ticker symbol "TSRO."

How were TESARO's earnings last quarter?

TESARO, Inc. (NASDAQ:TSRO) posted its quarterly earnings data on Tuesday, August, 8th. The company reported ($2.82) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($2.52) by $0.30. The firm earned $29.50 million during the quarter, compared to analysts' expectations of $18.61 million. TESARO had a negative return on equity of 104.00% and a negative net margin of 1,301.19%. TESARO's revenue for the quarter was down 17.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($1.28) earnings per share. View TESARO's Earnings History.

When will TESARO make its next earnings announcement?

TESARO is scheduled to release their next quarterly earnings announcement on Wednesday, November, 1st 2017. View Earnings Estimates for TESARO.

Where is TESARO's stock going? Where will TESARO's stock price be in 2017?

22 analysts have issued 12-month price targets for TESARO's stock. Their predictions range from $120.00 to $236.00. On average, they anticipate TESARO's share price to reach $169.82 in the next twelve months. View Analyst Ratings for TESARO.

What are analysts saying about TESARO stock?

Here are some recent quotes from research analysts about TESARO stock:

  • 1. According to Zacks Investment Research, "Tesaro, Inc. is an oncology-focused biopharmaceutical company for cancer patients. The Company's product portfolio consists of Rolapitant, a neurokinin-1 receptor antagonist for the prevention of chemotherapy induced nausea and vomiting, TSR-011, an orally available anaplastic lymphoma kinase inhibitor for the treatment of non-small cell lung cancer and other cancer indications, and Niraparib, an orally active and potent poly (ADP-ribose) polymerase inhibitor for the treatment of patients with solid tumors. Tesaro, Inc. is based in Waltham, Massachusetts. " (10/17/2017)
  • 2. Cann analysts commented, "These results are an analysis of the phase I/II TOPACIO study of niraparib plus pembrolizumab in combination with pembrolizumab (Keytruda) in patients with triple negative breast cancer (TNBC) or ovarian cancer. Safety and efficacy were presented from both the dose-finding portion as well as the dose-expansion portion of the study. We believe these data released today support a path forward for Tesaro in the TNBC setting with Zejula. TNBC is a particularly challenging setting. There are many studies from numerous drug sponsors underway and TNBC, but there is no established reference standard for this disease." (9/8/2017)
  • 3. FBR & Co analysts commented, "We received our first data snapshot from the RX-3117 Phase 2a study in advanced muscle invasive bladder cancer at ASCO this weekend with data coming from 10 patients in stage 1 of the study. The study achieved the predefined efficacy criteria (two of ten patients achieving a PFS of at least four months or a partial or complete tumor response), where 22% of patients have experienced PFS for a minimum of six months. One of the two aforementioned patients is still on study, achieving 175 days of stable disease. While only stage 1 of this study, we believe it is important to point out that patients who have reached this stage of disease are usually limited to palliative or best supportive care." (6/5/2017)
  • 4. Cowen and Company analysts commented, "TSRO reported 1Q financials, provided a pipeline update and commented on Zejula’s." (5/11/2017)
  • 5. Wedbush analysts commented, "With first-mover advantage in the maintenance setting, a lack of requirement for a diagnostic, as well clinical data that is at least as good as Lynparza in gBRCA patients, we continue to believe that TSRO remains an attractive acquisition candidate." (3/28/2017)

Are investors shorting TESARO?

TESARO saw a decline in short interest in the month of September. As of September 29th, there was short interest totalling 6,767,191 shares, a decline of 28.5% from the September 15th total of 9,459,637 shares. Based on an average trading volume of 570,698 shares, the days-to-cover ratio is currently 11.9 days. Approximately 17.9% of the company's stock are short sold.

Who are some of TESARO's key competitors?

Who are TESARO's key executives?

TESARO's management team includes the folowing people:

  • David M. Mott, Independent Chairman of the Board
  • Mary Lynne Hedley Ph.D., President, Chief Operating Officer, Director
  • Leon O. Moulder Jr., Chief Executive Officer, Director
  • Timothy R. Pearson, Chief Financial Officer, Executive Vice President
  • Jeffrey H. Hanke Ph.D., Executive Vice President - Research and Development, Chief Scientific Officer
  • Joseph L. Farmer, Senior Vice President, General Counsel, Secretary
  • Grant C. Bogle, Senior Vice President, Chief Commercial Officer
  • Martin H. Huber M.D., Senior Vice President and Chief Medical Officer
  • Lawrence M. Alleva, Independent Director
  • James O. Armitage M.D., Independent Director

How do I buy TESARO stock?

Shares of TESARO can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is TESARO's stock price today?

One share of TESARO stock can currently be purchased for approximately $113.60.

MarketBeat Community Rating for TESARO (NASDAQ TSRO)
Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  417 (Vote Outperform)
Underperform Votes:  236 (Vote Underperform)
Total Votes:  653
MarketBeat's community ratings are surveys of what our community members think about TESARO and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for TESARO (NASDAQ:TSRO) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 8 Hold Ratings, 14 Buy Ratings
Consensus Rating:Buy (Score: 2.64)
Consensus Price Target: $169.82 (49.49% upside)
Consensus Price Target History for TESARO (NASDAQ:TSRO)
Price Target History for TESARO (NASDAQ:TSRO)
Analysts' Ratings History for TESARO (NASDAQ:TSRO)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
10/12/2017HC WainwrightInitiated CoverageBuy -> Buy$158.00N/AView Rating Details
10/2/2017Robert W. BairdReiterated RatingNeutral$125.00LowView Rating Details
9/14/2017Royal Bank Of CanadaInitiated CoverageSector Perform$120.00MediumView Rating Details
9/11/2017WedbushReiterated RatingOutperform$160.00LowView Rating Details
9/10/2017Oppenheimer Holdings, Inc.Reiterated RatingBuy$199.00LowView Rating Details
9/11/2017Citigroup Inc.Reiterated RatingBuy$216.00LowView Rating Details
9/8/2017CannReiterated RatingBuy$199.00LowView Rating Details
8/20/2017SunTrust Banks, Inc.Reiterated RatingBuy$235.00HighView Rating Details
8/20/2017Wells Fargo & CompanyReiterated RatingOutperformHighView Rating Details
8/17/2017Jefferies Group LLCSet Price TargetHold$124.00HighView Rating Details
8/18/2017Credit Suisse GroupSet Price TargetBuy$198.00 -> $190.00HighView Rating Details
8/16/2017Evercore ISIInitiated CoverageIn -> In-Line$121.00HighView Rating Details
8/10/2017Morgan StanleyReiterated RatingOverweight$183.00HighView Rating Details
7/14/2017Janney Montgomery ScottReiterated RatingNeutralLowView Rating Details
7/7/2017GabelliInitiated CoverageBuy$175.00HighView Rating Details
6/20/2017Raymond James Financial, Inc.Reiterated RatingMarket PerformMediumView Rating Details
6/20/2017Leerink SwannLower Price TargetMarket Perform$164.00 -> $143.00HighView Rating Details
6/20/2017Bank of America CorporationReiterated RatingBuy$154.00HighView Rating Details
6/19/2017Cowen and CompanyLower Price TargetMarket Perform$145.00 -> $124.00HighView Rating Details
6/5/2017FBR & CoLower Price TargetMkt Perform -> Mkt Perform$200.00 -> $195.00HighView Rating Details
4/12/2017Piper Jaffray CompaniesInitiated CoverageOverweight -> Overweight$180.00LowView Rating Details
3/24/2017ArgusInitiated CoverageBuy$210.00HighView Rating Details
11/7/2016Lake Street CapitalReiterated RatingBuy$114.00 -> $150.00N/AView Rating Details
8/5/2016MizuhoLower Price TargetBuy$100.00 -> $94.00N/AView Rating Details
(Data available from 10/18/2015 forward)


Earnings History for TESARO (NASDAQ:TSRO)
Earnings by Quarter for TESARO (NASDAQ:TSRO)
Earnings History by Quarter for TESARO (NASDAQ TSRO)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/1/2017($1.16)N/AView Earnings Details
8/8/2017Q2 2017($2.52)($2.82)$18.61 million$29.50 millionViewListenView Earnings Details
5/9/2017Q1 2017($2.26)($2.55)$3.84 million$3.10 millionViewListenView Earnings Details
11/3/2016Q3($1.92)($1.98)$4.39 million$3.73 millionViewN/AView Earnings Details
5/5/2016Q1($1.69)($2.22)$2.48 million$0.31 millionViewN/AView Earnings Details
2/25/2016Q4($1.63)($1.89)$3.45 million$0.23 millionViewListenView Earnings Details
10/29/2015Q315($1.52)($1.66)$0.09 millionViewListenView Earnings Details
8/6/2015Q215($1.14)($1.51)ViewListenView Earnings Details
4/30/2015Q115($1.12)($1.30)ViewListenView Earnings Details
2/19/2015Q414($1.03)($1.33)ViewListenView Earnings Details
11/5/2014Q314($1.04)($1.01)ViewN/AView Earnings Details
7/24/2014Q214($0.87)($1.03)ViewN/AView Earnings Details
4/30/2014Q114($1.06)($1.43)ViewN/AView Earnings Details
2/19/2014Q413($0.78)($0.72)ViewN/AView Earnings Details
11/7/2013Q313($0.69)($0.88)ViewN/AView Earnings Details
7/25/2013Q2 2013($0.63)($0.67)ViewN/AView Earnings Details
4/25/2013Q1 2013($0.62)($0.66)ViewN/AView Earnings Details
2/14/2013Q4 2012($0.65)($15.41)ViewN/AView Earnings Details
10/25/2012($0.55)($0.52)ViewN/AView Earnings Details
7/26/2012($0.55)($4.11)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for TESARO (NASDAQ:TSRO)
2017 EPS Consensus Estimate: ($8.64)
2018 EPS Consensus Estimate: ($4.36)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20175($2.39)($1.98)($2.20)
Q2 20176($3.10)($2.15)($2.59)
Q3 20176($2.57)($0.52)($1.50)
Q4 20176($2.54)($1.86)($2.35)
Q1 20182($1.56)($1.32)($1.44)
Q2 20182($1.26)($0.93)($1.10)
Q3 20182($0.97)($0.92)($0.95)
Q4 20182($1.18)($0.57)($0.88)
(Data provided by Zacks Investment Research)


Dividend History for TESARO (NASDAQ:TSRO)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for TESARO (NASDAQ:TSRO)
Insider Ownership Percentage: 34.60%
Insider Trades by Quarter for TESARO (NASDAQ:TSRO)
Institutional Ownership by Quarter for TESARO (NASDAQ:TSRO)
Insider Trades by Quarter for TESARO (NASDAQ:TSRO)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/22/2017Martin H Jr. HuberSVPSell592$118.60$70,211.20View SEC Filing  
9/18/2017James O ArmitageDirectorSell10,000$117.13$1,171,300.00View SEC Filing  
9/6/2017Edward C EnglishVPSell10,862$134.92$1,465,501.04View SEC Filing  
9/5/2017Orlando OliveiraSVPSell71$132.66$9,418.86View SEC Filing  
9/1/2017Grant C. BogleVPSell14,167$135.00$1,912,545.00View SEC Filing  
6/6/2017Edward C EnglishVPSell8,500$138.65$1,178,525.00View SEC Filing  
4/3/2017Martin H Jr. HuberSVPSell829$153.02$126,853.58View SEC Filing  
3/6/2017Edward C EnglishVPSell10,000$178.06$1,780,600.00View SEC Filing  
3/2/2017Edward C EnglishVPSell229$177.61$40,672.69View SEC Filing  
3/2/2017Grant C. BogleSVPSell1,447$177.61$257,001.67View SEC Filing  
3/2/2017Mary Lynne HedleyCOOSell3,927$177.61$697,474.47View SEC Filing  
1/3/2017Martin H. Jr. HuberSVPSell190$136.26$25,889.40View SEC Filing  
11/2/2016Martin H Jr. HuberSVPSell327$121.29$39,661.83View SEC Filing  
9/22/2016Martin H Jr. HuberSVPSell408$108.12$44,112.96View SEC Filing  
9/8/2016Edward C EnglishVPSell7,000$88.54$619,780.00View SEC Filing  
8/30/2016Jeffrey H HankeVPSell29,166$86.04$2,509,442.64View SEC Filing  
6/30/2016Jeffrey H HankeVPSell12,500$74.35$929,375.00View SEC Filing  
6/10/2016Edward C EnglishVPSell7,000$40.75$285,250.00View SEC Filing  
3/18/2016Arnold L OronskyDirectorBuy142,085$35.19$4,999,971.15View SEC Filing  
3/18/2016Enterprise Associates 13 L NewMajor ShareholderBuy710,429$35.19$24,999,996.51View SEC Filing  
3/10/2016Edward C EnglishVPSell7,000$43.71$305,970.00View SEC Filing  
12/10/2015Edward C. EnglishVPSell17,000$50.19$853,230.00View SEC Filing  
9/8/2015James O ArmitageDirectorBuy500$54.63$27,315.00View SEC Filing  
12/12/2014James O ArmitageDirectorBuy1,000$38.16$38,160.00View SEC Filing  
9/29/2014Lawrence M AllevaDirectorBuy1,100$26.17$28,787.00View SEC Filing  
7/31/2013Lawrence M AllevaDirectorBuy1,449$34.33$49,744.17View SEC Filing  
6/5/2013Peter J BarrisMajor ShareholderSell3,583$39.00$139,737.00View SEC Filing  
4/30/2013Lawrence M AllevaDirectorBuy1,050$28.10$29,505.00View SEC Filing  
11/1/2012Lawrence M AllevaDirectorBuy3,240$15.45$50,058.00View SEC Filing  
8/30/2012Leon O Moulder JrCEOBuy10,000$11.69$116,900.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for TESARO (NASDAQ:TSRO)
Latest Headlines for TESARO (NASDAQ:TSRO)
americanbankingnews.com logoTESARO, Inc. (TSRO) Receives New Coverage from Analysts at HC Wainwright
www.americanbankingnews.com - October 15 at 7:56 AM
americanbankingnews.com logoTESARO, Inc. (TSRO) Short Interest Update
www.americanbankingnews.com - October 13 at 1:58 AM
finance.yahoo.com logoThe Zacks Analyst Blog Highlights: Flexion Therapeutics, Alexion Pharmaceuticals, PTC Therapeutics, Johnson & Johnson and TESARO
finance.yahoo.com - October 6 at 11:51 AM
finance.yahoo.com logoAre Options Traders Betting on a Big Move in Tesaro (TSRO) Stock?
finance.yahoo.com - October 6 at 11:51 AM
nasdaq.com logoFirst Week of TSRO November 17th Options Trading
www.nasdaq.com - October 3 at 1:56 PM
americanbankingnews.com logo$118.02 Million in Sales Expected for TESARO Inc (TSRO) This Quarter
www.americanbankingnews.com - October 3 at 1:36 AM
americanbankingnews.com logoTESARO, Inc. (TSRO) Receives Neutral Rating from Robert W. Baird
www.americanbankingnews.com - October 2 at 3:50 PM
americanbankingnews.com logo-$1.19 EPS Expected for TESARO, Inc. (TSRO) This Quarter
www.americanbankingnews.com - October 1 at 10:26 PM
americanbankingnews.com logoAnalyzing TESARO (TSRO) and Ultragenyx Pharmaceutical (RARE)
www.americanbankingnews.com - October 1 at 2:20 PM
globenewswire.com logoTESARO Expands Our Way Forward Program for the Ovarian Cancer Community and Partners With Olympic Gymnast ... - GlobeNewswire (press release)
globenewswire.com - September 30 at 7:49 PM
americanbankingnews.com logoTESARO, Inc. (TSRO) SVP Sells $70,211.20 in Stock
www.americanbankingnews.com - September 25 at 7:36 PM
americanbankingnews.com logoTESARO, Inc. (TSRO) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - September 24 at 8:34 PM
americanbankingnews.com logoJames O. Armitage Sells 10,000 Shares of TESARO, Inc. (TSRO) Stock
www.americanbankingnews.com - September 20 at 7:56 PM
globenewswire.com logoTESARO Receives Positive CHMP Opinion for ZEJULA® - GlobeNewswire (press release)
globenewswire.com - September 16 at 9:53 AM
americanbankingnews.com logo$118.02 Million in Sales Expected for TESARO, Inc. (TSRO) This Quarter
www.americanbankingnews.com - September 15 at 11:00 AM
americanbankingnews.com logoTESARO, Inc. (TSRO) Now Covered by Analysts at Royal Bank Of Canada
www.americanbankingnews.com - September 14 at 6:06 PM
americanbankingnews.com logo Brokerages Expect TESARO, Inc. (TSRO) to Post -$1.19 EPS
www.americanbankingnews.com - September 13 at 4:26 AM
americanbankingnews.com logoTESARO, Inc. (TSRO) Rating Reiterated by Wedbush
www.americanbankingnews.com - September 11 at 5:46 PM
americanbankingnews.com logoCitigroup Inc. Reaffirms "Buy" Rating for TESARO, Inc. (TSRO)
www.americanbankingnews.com - September 11 at 3:50 PM
americanbankingnews.com logoOppenheimer Holdings, Inc. Reaffirms "Buy" Rating for TESARO, Inc. (TSRO)
www.americanbankingnews.com - September 11 at 3:12 PM
benzinga.com logoTesaro Sheds $20 Over The Last Three Days
www.benzinga.com - September 8 at 8:35 PM
americanbankingnews.com logoTESARO, Inc. (TSRO) Receives "Buy" Rating from Cann
www.americanbankingnews.com - September 8 at 1:16 PM
americanbankingnews.com logoGrant C. Bogle Sells 14,167 Shares of TESARO, Inc. (TSRO) Stock
www.americanbankingnews.com - September 6 at 10:28 PM
americanbankingnews.com logoInsider Selling: TESARO, Inc. (TSRO) VP Sells 10,862 Shares of Stock
www.americanbankingnews.com - September 6 at 10:26 PM
americanbankingnews.com logoTESARO, Inc. (TSRO) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - August 30 at 8:36 PM
americanbankingnews.com logoTESARO, Inc. (TSRO) Expected to Post Quarterly Sales of $118.02 Million
www.americanbankingnews.com - August 27 at 3:56 AM
americanbankingnews.com logo Brokerages Expect TESARO, Inc. (TSRO) Will Announce Earnings of -$1.19 Per Share
www.americanbankingnews.com - August 25 at 4:28 PM
nasdaq.com logoTESARO? Announces Participation at Four Investor Conferences
www.nasdaq.com - August 24 at 3:57 PM
finance.yahoo.com logoTESARO, Inc. :TSRO-US: Earnings Analysis: Q2, 2017 By the Numbers : August 24, 2017
finance.yahoo.com - August 24 at 3:57 PM
americanbankingnews.com logoTESARO, Inc. (TSRO) Receives "Buy" Rating from SunTrust Banks, Inc.
www.americanbankingnews.com - August 20 at 9:42 AM
americanbankingnews.com logoTESARO, Inc. (TSRO) Receives "Outperform" Rating from Wells Fargo & Company
www.americanbankingnews.com - August 20 at 9:42 AM
barrons.com logoTesaro: Losing Its Edge? - Barron's
www.barrons.com - August 19 at 8:27 AM
americanbankingnews.com logoJefferies Group LLC Reiterates $124.00 Price Target for TESARO, Inc. (TSRO)
www.americanbankingnews.com - August 18 at 11:22 AM
americanbankingnews.com logoTESARO, Inc. (TSRO) Given a $190.00 Price Target by Credit Suisse Group Analysts
www.americanbankingnews.com - August 18 at 8:12 AM
americanbankingnews.com logoTESARO, Inc. (TSRO) Research Coverage Started at Evercore ISI
www.americanbankingnews.com - August 16 at 6:58 PM
finance.yahoo.com logoSee what the IHS Markit Score report has to say about TESARO Inc.
finance.yahoo.com - August 15 at 1:36 AM
americanbankingnews.com logoResearch Analysts Offer Predictions for TESARO, Inc.'s Q3 2017 Earnings (NASDAQ:TSRO)
www.americanbankingnews.com - August 11 at 11:40 AM
americanbankingnews.com logoTESARO, Inc. (NASDAQ:TSRO) Expected to Post Q3 2017 Earnings of ($0.66) Per Share
www.americanbankingnews.com - August 11 at 11:40 AM
americanbankingnews.com logoTESARO, Inc. Expected to Post Q3 2017 Earnings of ($0.56) Per Share (NASDAQ:TSRO)
www.americanbankingnews.com - August 11 at 11:40 AM
americanbankingnews.com logoGabelli Brokers Lower Earnings Estimates for TESARO, Inc. (TSRO)
www.americanbankingnews.com - August 11 at 10:14 AM
americanbankingnews.com logoQ3 2017 EPS Estimates for TESARO, Inc. Cut by Analyst (TSRO)
www.americanbankingnews.com - August 11 at 7:48 AM
americanbankingnews.com logoQ3 2017 EPS Estimates for TESARO, Inc. (TSRO) Boosted by Wedbush
www.americanbankingnews.com - August 11 at 7:48 AM
americanbankingnews.com logoTESARO, Inc. (NASDAQ:TSRO) to Post FY2020 Earnings of $6.84 Per Share, SunTrust Banks Forecasts
www.americanbankingnews.com - August 10 at 1:50 PM
americanbankingnews.com logoOppenheimer Holdings Analysts Lift Earnings Estimates for TESARO, Inc. (NASDAQ:TSRO)
www.americanbankingnews.com - August 10 at 1:32 PM
americanbankingnews.com logoTESARO's (NASDAQ:TSRO) Neutral Rating Reiterated at Robert W. Baird
www.americanbankingnews.com - August 10 at 12:46 PM
americanbankingnews.com logoTESARO, Inc. (NASDAQ:TSRO) Announces Quarterly Earnings Results, Misses Estimates By $0.30 EPS
www.americanbankingnews.com - August 9 at 3:48 PM
americanbankingnews.com logo$16.29 Million in Sales Expected for TESARO, Inc. (NASDAQ:TSRO) This Quarter
www.americanbankingnews.com - August 9 at 7:52 AM
feeds.benzinga.com logoA Biotech Binary Event Playbook: How To Play Clovis And Tesaro Ahead Of Label Decision
feeds.benzinga.com - August 8 at 3:23 PM
americanbankingnews.com logo-$2.52 EPS Expected for TESARO, Inc. (NASDAQ:TSRO) This Quarter
www.americanbankingnews.com - August 7 at 8:54 AM
nasdaq.com logoWhy Earnings Season Could Be Great for TESARO (TSRO) - Nasdaq
www.nasdaq.com - August 6 at 6:47 AM



TESARO (TSRO) Chart for Wednesday, October, 18, 2017

This page was last updated on 10/18/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.